Search

Meet KeyZell, our new member. We talked to its José del Corral, CEO.

The Spanish Agency for Medicines and Health Products (AEMPS) has certified compliance with the European Union Good Manufacturing Practices (GMP).

BIOLAN Microbiosensores, a world leader in biosensor technology applied to the food sector, has just launched its new development for the quantification of the SALT BIOFISH 7000 SALT is a unique

Dr. Manuel Hidalgo is working with Peaches Biotech in the development of a new treatment called opT cells, born from a collaborative project with Harvard Medical School.

ApTOLL shows potential for slowing the progression of multiple sclerosis (MS) in preclinical animal studies.

Nitrosamines represent a significant health risk, being potentially carcinogenic and a major concern in pharmaceutical manufacturing processes.

Meet Kirsch Pharma, our new member. We talked to its Raquel Márquez Duro, Key Account Mánager de España y Portugal.

To address how biotechnology is enabling progress in combating obesity from various perspectives, and in celebration of European Obesity Day, we interviewed Miriam Rubio de Santos, Medical Director of

At the regulatory and political level, Spain has had the Integral Bioeconomy Strategy since 2015, but it has barely evolved over time and has not achieved a significant impact.

During the AseBio Investor Day, held on May 15th in San Sebastián, AseBio has revealed data on private financing collected in the AseBio 2023 Report.

Oryzon Genomics will attend and participate, both as speaker and guest, in different events related to biotechnology and investment.

Hector Olabegogeaskoetxea Narbaiza, CEO of MONDRAGON Health, Silver Sponsor of AseBio Investor Day, analyzes the biotech innovation ecosystem in Spain.

Companies connected to the Barcelona Science Park received €85.4 million in 2023, 38.6% of the total funding in the BioRegion of Catalonia, €220 million, according to the BioRegion of Catalonia Report

Finalizing full data analysis from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD) Company planning to request an End-of-Phase II meeting with the FDA to discuss plans

Meet Appliant, our new member. We talked to its Marc Ramoneda, Partner & CEO.

We analyze the challenges that biotechnology companies face in terms of financing, with David Roberto García, Chief Financial Officer of Laminar Pharma, Silver Sponsor of AseBio Investor Day 2024.

We interviewed Roger Pique, General Partner at Inveready, Bronze Sponsor of the AseBio Investor Day 2024.

BIOFISH 7000 SAL is a unique device because it is connected to the cloud, faster, more accurate, versatile in the sample to be measured, and quantifies salt by measuring sodium, a real factor of

The Biscayan biopharmaceutical company, which plans to launch its first biological medicine into the market in the first half of 2025, will use the funds to expand its manufacturing capacity and

The main objective of the project is the creation of innovative in vitro models using microencapsulation of human liver cells by means of bioprinting systems.

In addition to this rating, earlier this year, CDP recognized the company for its transparency and efforts against climate change.